With the continuous development and improvement of China's science and technology and medical technology, the HPV vaccine has changed from imported to domestic! This is undoubtedly a boon for female friends! So, what is the difference between the production of domestic HPV vaccine and imported vaccine? Come together Let's see!
What is the difference between domestic and imported HPV vaccines?
The first domestic HPV vaccine started to be produced at 329 yuan each! The parent company is expected to enter the market in May just after the IPO!
The launch of the vaccine means that the end of China's cervical cancer vaccine can only rely on the history of imports.
This product was jointly developed by Xia Ningshao's team at Xiamen University and Xiamen Wantai. It is the first domestic human papilloma virus vaccine approved and is suitable for women aged 9-45.
According to Xiamen Wantai News, Xin Ke Ning is priced at 329 yuan / piece. Women 9-14 years old need only 2 shots, and women 15-45 years old get 3 shots. The product is currently ready for production.
So, many people want to know the difference between domestic HPV vaccine and imported HPV vaccine?
1. Age difference of vaccination
The difference is mainly the difference between the vaccinated objects! The age of domestic HPV vaccination is 9-45 years old women, while 9-26 years old can be vaccinated with 9-valent vaccine, and 26-year-old is generally vaccinated with 4-valent vaccine! Because it is considered that less than 26 years old is The period when sexual intercourse is the lowest, 9-valent vaccine is most effective during this period!
The imported HPV vaccination target is that women under 45 years old can receive 9- and 4-valent vaccines!
2. Price difference
In the face of several products that have already been marketed in China and have first-mover advantages, and the protection rate is not much different, the price of Xinkening's 329 yuan per support is 660 yuan for two injections and 1,000 yuan for three injections. More price advantage.
The imported HPV vaccine is more expensive. At present, HPV vaccine can be vaccinated at Guangdong Community Health Service Centers such as Guangshen. The manufacturer of the bivalent vaccine is GlaxoSmithKline of the United Kingdom, and the Mercury Company of the four and nine prices.
Bivalent HPV vaccine, suitable for 9 to 45-year-old women. One dose of 580 yuan / dose will be inoculated at 0, 1, and 6 months. Three doses of vaccination will be required. The injection fee will be 25 yuan / time. Three injections will total 1815 yuan.
A four-valent HPV vaccine, suitable for women aged 20 to 45 years. One dose of 798 yuan / dose will be inoculated at 0, 2, and 6 months. Three doses of vaccination will be required. The injection cost will be 25 yuan / time.
Nine-valent HPV vaccine, suitable for women aged 16 to 26, inoculated with one dose at 0, 2, and 6 months, 1298 yuan / dose, 3 doses are needed, 25 yuan / time for injection, 3969 yuan for 3 injections;
Therefore, the price is also a big difference! Many people worry that the price difference will be different if there is a difference? This is not a concern! The domestic HPV vaccine is also a vaccine certified by the national health department and is authoritative and safe. Sexual!
3. Differences in vaccine types:
There are currently 3 types of HPV vaccines that have been marketed worldwide, namely:
GlaxoSmithKline's bivalent vaccine against HPV16, 18,
Tetravalent vaccine against HPV6, 11, 16, 18 produced by Merck
A nine-valent vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52, 58 produced by Merck Company in the United States.
The bivalent human papillomavirus vaccine approved this time is the first HPV vaccine declared for production in China. It is targeted at HPV16 and 18 types and has been included in the national major new drug creation special support.
According to Xiamen Wantai News, Xinkening is priced at 329 yuan / piece. Females 9-14 years old need only 2 shots, and 15-45-year-old women get 3 shots. Enter the production line and be available in bulk at the latest in May this year.
It is worth mentioning that according to the "Time Finance" report under the Times Weekly, Tao Lina, a vaccine industry expert who has worked in the Shanghai Center for Disease Control and Prevention for 15 years, believes that the domestic market of the bivalent cervical cancer vaccine is a "milestone". Meaning, but purely from a technical point of view, this domestic vaccine "can only be considered satisfactory and has no special highlights."
According to its introduction, GlaxoSmithKline's bivalent HPV vaccine uses a new adjuvant technology that has won the Nobel Prize for its principle and is targeting two high-risk HPV viruses (HPV-16 and HPV- 18) Higher antibodies are produced. Tao Linna believes that compared with imported vaccines, current domestic vaccines "do not have a key advantage."
Tao Linna believes that the key is how to promote the vaccine in the domestic market. In his opinion, the promotion of this domestic vaccine in first-tier cities is more difficult. On the one hand, compared with imported vaccines, domestic vaccines are not enough in terms of price competitiveness; on the other hand, people in first-tier cities generally They have a better understanding and are more recognizable of the nine-valent vaccine.
But he believes that compared with first-tier cities, audiences in second- and third-tier cities will be more likely to accept domestic vaccines. "If government procurement policies in some regions can be implemented, it is likely that domestic vaccines will become a priority for the government."
According to the latest research, adolescents need only one dose of cervical cancer vaccine to achieve preventive effects. With fewer injections and lower prices, the probability of free vaccination among adolescents in China will increase. Some people in the industry believe that in the context of many developed countries that have included cervical cancer vaccines in the ranks of free vaccination, it is only a matter of time for China to achieve free vaccination of such vaccines.
Therefore, we also look forward to the future government to improve the content of vaccination policy, after all, this is something that is meaningful to all women and men!
The above is the introduction of the differences between the domestic HPV vaccine and the domestic vaccine and the imported vaccine! I hope to help you!
hpv疫苗哪些人不能打打hpv疫苗必知小知识 Suggested Reading: HPV Vaccine Who Should Not Get HPV Vaccine Must Know